You just read:

Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Dry Age-Related Macular Degeneration with Geographic Atrophy

News provided by

Stealth BioTherapeutics

Dec 10, 2018, 09:00 ET